iTeos to Present at the 43rd Annual J.P. Morgan Healthcare Conference
iTeos Therapeutics (Nasdaq: ITOS), a clinical-stage biopharmaceutical company focused on developing innovative immuno-oncology therapeutics, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's President and CEO, Michel Detheux, Ph.D., will deliver a presentation on Wednesday, January 15, 2025, at 7:30 AM PST (10:30 AM EST) in San Francisco.
Interested parties can access a live webcast of the presentation through the Investors section of iTeos's website at www.iteostherapeutics.com. The presentation recording will remain available for approximately 30 days after the event.
iTeos Therapeutics (Nasdaq: ITOS), un'azienda biofarmaceutica in fase clinica focalizzata sullo sviluppo di terapie immuno-oncologiche innovative, ha annunciato la sua partecipazione alla 43ª Conferenza Annuale J.P. Morgan Healthcare. Il Presidente e CEO dell'azienda, Michel Detheux, Ph.D., presenterà un intervento mercoledì 15 gennaio 2025, alle 7:30 AM PST (10:30 AM EST) a San Francisco.
Le parti interessate possono accedere a una trasmissione in diretta della presentazione attraverso la sezione Investitori del sito web di iTeos all'indirizzo www.iteostherapeutics.com. La registrazione della presentazione sarà disponibile per circa 30 giorni dopo l'evento.
iTeos Therapeutics (Nasdaq: ITOS), una empresa biofarmacéutica en etapa clínica enfocada en el desarrollo de terapias innovadoras de inmuno-oncología, ha anunciado su participación en la 43ª Conferencia Anual de J.P. Morgan Healthcare. El Presidente y CEO de la empresa, Michel Detheux, Ph.D., ofrecerá una presentación el miércoles 15 de enero de 2025, a las 7:30 AM PST (10:30 AM EST) en San Francisco.
Las partes interesadas pueden acceder a una transmisión en vivo de la presentación a través de la sección de Inversores del sitio web de iTeos en www.iteostherapeutics.com. La grabación de la presentación estará disponible durante aproximadamente 30 días después del evento.
iTeos Therapeutics (Nasdaq: ITOS), 혁신적인 면역 항암 치료제를 개발하는 임상 단계의 생명공학 회사가 제43회 JP 모건 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 회사의 회장兼 CEO인 Michel Detheux, Ph.D.가 2025년 1월 15일 수요일, 오전 7시 30분 PST (오후 10시 30분 EST)에 샌프란시스코에서 발표를 진행합니다.
관심 있는 분들은 iTeos 웹사이트의 투자자 섹션을 통해 발표의 라이브 웹캐스트에 접근할 수 있습니다: www.iteostherapeutics.com. 발표 녹음은 행사 종료 후 약 30일 동안 이용 가능합니다.
iTeos Therapeutics (Nasdaq: ITOS), une entreprise biopharmaceutique en phase clinique spécialisée dans le développement de thérapies immuno-oncologiques innovantes, a annoncé sa participation à la 43ème Conférence Annuelle J.P. Morgan Healthcare. Le Président et CEO de l'entreprise, Michel Detheux, Ph.D., fera une présentation le mercredi 15 janvier 2025, à 7h30 PST (10h30 EST) à San Francisco.
Les parties intéressées peuvent accéder à un webcast en direct de la présentation via la section Investisseurs du site web d'iTeos à l'adresse www.iteostherapeutics.com. L'enregistrement de la présentation sera disponible pendant environ 30 jours après l'événement.
iTeos Therapeutics (Nasdaq: ITOS), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf die Entwicklung innovativer immunonkologischer Therapeutika konzentriert, hat seine Teilnahme an der 43. jährlichen J.P. Morgan Healthcare-Konferenz bekannt gegeben. Der Präsident und CEO des Unternehmens, Michel Detheux, Ph.D., wird am Mittwoch, den 15. Januar 2025, um 7:30 Uhr PST (10:30 Uhr EST) in San Francisco eine Präsentation halten.
Interessierte können die Live-Übertragung der Präsentation über den Bereich Investoren auf der Website von iTeos unter www.iteostherapeutics.com abrufen. Die Aufzeichnung der Präsentation wird etwa 30 Tage nach der Veranstaltung zur Verfügung stehen.
- None.
- None.
WATERTOWN, Mass. and GOSSELIES, Belgium, Jan. 08, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that Michel Detheux, Ph.D., President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA on Wednesday, January 15, 2025 at 7:30 AM PST (10:30 AM EST).
A live webcast of the presentation will be available on the Investors section of the Company’s website at www.iteostherapeutics.com. An archived replay will be available for approximately 30 days following the presentation.
About iTeos Therapeutics, Inc.
iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of tumor immunology and immunosuppressive pathways to design novel product candidates with the potential to restore the immune response against cancer. The Company’s innovative pipeline includes three clinical-stage programs targeting novel, validated immunosuppressive pathways designed with optimized pharmacologic properties for improved clinical outcomes. iTeos Therapeutics is headquartered in Watertown, MA with a research center in Gosselies, Belgium.
Internet Posting of Information
iTeos routinely posts information that may be important to investors in the 'Investors' section of its website at www.iteostherapeutics.com. The Company encourages investors and potential investors to consult our website regularly for important information about iTeos.
For further information, please contact:
Investor Contact:
Carl Mauch
iTeos Therapeutics, Inc.
carl.mauch@iteostherapeutics.com
Media Contact:
media@iteostherapeutics.com
FAQ
When is iTeos Therapeutics (ITOS) presenting at the 2025 J.P. Morgan Healthcare Conference?
How can investors watch iTeos Therapeutics' (ITOS) J.P. Morgan Healthcare Conference presentation?
How long will iTeos Therapeutics' (ITOS) J.P. Morgan presentation replay be available?
Who is presenting for iTeos Therapeutics (ITOS) at the 2025 J.P. Morgan Healthcare Conference?
